Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 18/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13889058 | 0.94 | NR3C1 (0.88) | NR3C1P2RX7 | |
| SCHEMBL4515058 | 0.93 | NR3C1 (1.00) | NR3C1 | |
| SCHEMBL4515936 | 0.87 | NR3C1 (0.79) | NR3C1CYP3A4CYP2D6 | |
| SCHEMBL4517776 | 0.86 | NR3C1 (0.75) | NR3C1CYP3A4CYP2D6 | |
| SCHEMBL4510389 | 0.79 | NR3C1 (0.75) | NR3C1CYP3A4P2RX7CYP2D6 | |
| SCHEMBL4520415 | 0.79 | NR3C1 (1.00) | NR3C1 | |
| SCHEMBL4527332 | 0.78 | NR3C1 (0.71) | NR3C1PGR | |
| SCHEMBL4107265 | 0.77 | NR3C1 (0.71) | NR3C1CYP3A4CYP2C9PGR | |
| SCHEMBL4512972 | 0.76 | NR3C1 (0.66) | NR3C1CYP3A4CYP2D6 | |
| SCHEMBL4525697 | 0.76 | NR3C1 (0.66) | NR3C1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | NR3C1, NR3C2, NR5A1 | NR3C1 1/4885CYP3A4 887/4885CYP2C9 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.